• Cytokinetics Inc., of South San Francisco, expects to receive $60 million in gross proceeds from two offerings. It priced a public offering of 55.9 million shares of common stock and warrants to purchase 0.6 shares of common stock for 76 cents per unit, raising $42.5 million. The company also offered 23,026 shares of its Series B convertible preferred stock and warrants to purchase 600 shares of common stock for each share of Series B purchased, at $760 each, raising about $17.5 million. Each Series B share is convertible into 1,000 shares of common stock. The warrants in both offerings are exercisable at 88 cents per share. Cowen and Co. LLC and JMP Securities LLC are acting as lead underwriters, with Canaccord Genuity and Needham & Co. acting as co-managers.

• Stemline Therapeutics Inc., of New York, added an underwriter to its pending initial public offering. JMP Securities will be a co-manager, along with co-leads RBC Capital Markets and Oppenheimer & Co. The number of shares to be offered and the offering price are not yet disclosed. The company intends to list its stock on Nasdaq under the symbol, "STML." (See BioWorld Today, May 17, 2012.)